BR112018076666A2 - cilastatina para uso no tratamento de sépsis - Google Patents
cilastatina para uso no tratamento de sépsisInfo
- Publication number
- BR112018076666A2 BR112018076666A2 BR112018076666-6A BR112018076666A BR112018076666A2 BR 112018076666 A2 BR112018076666 A2 BR 112018076666A2 BR 112018076666 A BR112018076666 A BR 112018076666A BR 112018076666 A2 BR112018076666 A2 BR 112018076666A2
- Authority
- BR
- Brazil
- Prior art keywords
- sepsis
- cilastatin
- treatment
- aki
- methods
- Prior art date
Links
- 206010040047 Sepsis Diseases 0.000 title abstract 5
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 title abstract 2
- 229960004912 cilastatin Drugs 0.000 title abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção se refere ao tratamento de sépsis e lesão renal aguda associada com a sépsis (sa-aki). mais especificamente, se refere à cilastatina para uso em um método de tratamento de sépsis e/ou sa-aki e redução de sua mortalidade associada, em um indivíduo mamífero. é ainda direcionada aos métodos para o tratamento de sépsis e/ou sa-aki; e às composições farmacêuticas para uso nos métodos da invenção.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382299 | 2016-06-24 | ||
EP16382299.2 | 2016-06-24 | ||
PCT/EP2017/065609 WO2017220810A1 (en) | 2016-06-24 | 2017-06-23 | Cilastatin for use in the treatment of sepsis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018076666A2 true BR112018076666A2 (pt) | 2019-04-02 |
Family
ID=56345070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018076666-6A BR112018076666A2 (pt) | 2016-06-24 | 2017-06-23 | cilastatina para uso no tratamento de sépsis |
Country Status (9)
Country | Link |
---|---|
US (1) | US11185522B2 (pt) |
EP (1) | EP3474897B1 (pt) |
JP (1) | JP7109791B2 (pt) |
CN (1) | CN109843330B (pt) |
AU (1) | AU2017281744B2 (pt) |
BR (1) | BR112018076666A2 (pt) |
CA (1) | CA3028846A1 (pt) |
ES (1) | ES2864168T3 (pt) |
WO (1) | WO2017220810A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL257458B2 (en) | 2015-08-11 | 2024-01-01 | Arch Biopartners Inc | DPEP-1 binding compositions and methods of use |
US20230165792A1 (en) * | 2020-04-30 | 2023-06-01 | Denka Company Limited | Liquid formulation and pharmaceutical product containing cilastatin |
NL2025730B1 (en) | 2020-06-02 | 2022-01-20 | Sulfateq Bv | Compounds for treatment of sepsis |
WO2022191828A1 (en) * | 2021-03-10 | 2022-09-15 | Wen Tan | NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668504A (en) | 1970-11-18 | 1987-05-26 | Merck & Co., Inc. | Use of substituted propenoates to prevent nephrotoxicity of certain antibiotics |
AU2556597A (en) | 1996-04-04 | 1997-10-29 | Merck & Co., Inc. | Method of reducing nephrotoxicity |
CN1878564A (zh) * | 2003-09-12 | 2006-12-13 | 科罗拉多州大学评议会 | 用于治疗损伤的谷氨酰胺 |
JPWO2005037265A1 (ja) | 2003-10-17 | 2006-12-28 | 三菱ウェルファーマ株式会社 | 併用薬剤 |
WO2010004060A1 (es) * | 2008-07-11 | 2010-01-14 | Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon | Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos |
TWI558403B (zh) | 2013-06-04 | 2016-11-21 | 中央研究院 | 富含半乳糖脂之植物萃取物及其用途 |
WO2015111666A1 (ja) | 2014-01-24 | 2015-07-30 | 味の素株式会社 | メガリン拮抗剤 |
IL257458B2 (en) | 2015-08-11 | 2024-01-01 | Arch Biopartners Inc | DPEP-1 binding compositions and methods of use |
-
2017
- 2017-06-23 CA CA3028846A patent/CA3028846A1/en active Pending
- 2017-06-23 WO PCT/EP2017/065609 patent/WO2017220810A1/en unknown
- 2017-06-23 ES ES17731188T patent/ES2864168T3/es active Active
- 2017-06-23 CN CN201780052286.XA patent/CN109843330B/zh active Active
- 2017-06-23 EP EP17731188.3A patent/EP3474897B1/en active Active
- 2017-06-23 JP JP2019520490A patent/JP7109791B2/ja active Active
- 2017-06-23 AU AU2017281744A patent/AU2017281744B2/en active Active
- 2017-06-23 BR BR112018076666-6A patent/BR112018076666A2/pt not_active Application Discontinuation
- 2017-06-23 US US16/312,825 patent/US11185522B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN109843330A (zh) | 2019-06-04 |
CA3028846A1 (en) | 2017-12-28 |
EP3474897B1 (en) | 2021-01-27 |
EP3474897A1 (en) | 2019-05-01 |
AU2017281744B2 (en) | 2022-10-27 |
CN109843330B (zh) | 2022-08-23 |
US20200069623A1 (en) | 2020-03-05 |
JP7109791B2 (ja) | 2022-08-01 |
WO2017220810A1 (en) | 2017-12-28 |
AU2017281744A1 (en) | 2019-01-17 |
JP2019525954A (ja) | 2019-09-12 |
ES2864168T3 (es) | 2021-10-13 |
US11185522B2 (en) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
BR112018000632A8 (pt) | Moléculas de anticorpo que ligam a cd79 | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
BR112018070859A2 (pt) | degradantes da proteína de bet | |
BR112017025813A2 (pt) | método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana | |
BR112018076666A2 (pt) | cilastatina para uso no tratamento de sépsis | |
BR112015001768A2 (pt) | método e dispositivo para processamento de modo infantil | |
BR112017007379A2 (pt) | moléculas de anticorpo para pd-l1 e usos das mesmas | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
BR112018007809A2 (pt) | composição de agente de resistência a seco, método para melhorar a força a seco de papel, e, uso de uma composição | |
BR112019009256A2 (pt) | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo | |
BR112017001339A2 (pt) | método, pasta de cimento e sistema | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
BR112015018948A2 (pt) | produtos alimentícios com sódio reduzido | |
BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
BR112018013272A2 (pt) | composições e métodos para detectar e tratar câncer esofágico | |
BR112012028668A2 (pt) | emulsão, processo para preparar a emulsão, e, uso | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
BR112018013268A2 (pt) | composições e métodos para detectar e tratar câncer gástrico | |
BR112017011916A2 (pt) | agente para tratamento de deformação de cabelo | |
AU2017261919A1 (en) | Fat and medical uses thereof | |
BR112018013271A2 (pt) | composições e métodos para detectar e tratar câncer de ovário |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |